Med-tech firms raising money in public or private financings, including: Neuvotion, Nyxoah.

Med-tech firms raising money in public or private financings, including: Bioventrix, Evoendo, Glucotrack, Neuromod, Saluda.

Function Oncology Inc. emerged from stealth on April 12 with the announcement of a $28 million series A financing that will continue support development of its CRISPR-enabled platform to profile cancer in patient-specific detail. The platform goes beyond next-generation sequencing to measure gene function, potentially allowing identification of new therapeutic targets and better matching of available therapies to vulnerabilities in an individual’s tumors.

Med-tech firms raising money in public or private financings, including: Milkmate Products, Oncosec Medical, Overwater Ventures, Scene Health.

Med-tech firms raising money in public or private financings, including: Oshi Health, Sentiar.

Med-tech firms raising money in public or private financings, including: Anpac Bio-Medical Science.

Heartflow Inc. is feeling the love of investors again as it closed a $215 series F financing round led by Bain Capital Life Sciences. The round marks a return to the equity markets after several years away; the company closed its series E in 2017 and a $65 million venture round in 2019. In early 2022, Heartflow scrapped its plans to go public through a special purchase acquisition company (SPAC) merger with Longview Acquisition, citing what both companies called “current unfavorable market conditions.” Longview had offered $690 million in July 2021, in a deal that implied an enterprise value of $2.4 billion at the time.

Med-tech firms raising money in public or private financings, including: Celularity, Felix Health, G Medical Innovations, Occlutech.